Form 4: Bausch + Lomb Director Receives Annual RSU Grant

Bausch + Lomb Director Steven H. Collis was granted 5,255 restricted share units as part of the company's 2022 Omnibus Incentive Plan.

Summary

• Steven H. Collis, a Director of Bausch + Lomb Corporation (BLCO), received an annual grant of 5,255 restricted share units (RSUs).
• The RSUs were granted on February 19, 2026, at a price of $0 per unit, indicating an equity award rather than a purchase.
• This grant is made under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
• The RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders and will be settled in common shares, no par value, of Bausch + Lomb Corporation.
• Following this reported transaction, Mr. Collis directly beneficially owns 5,255 common shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard corporate governance practices that align director incentives with long-term shareholder interests.

Positives

• The grant of restricted share units to Director Steven H. Collis aligns his interests with those of shareholders, promoting long-term value creation.
• The use of the established 2022 Omnibus Incentive Plan demonstrates a structured and transparent approach to director compensation.

Future Outlook

The granted restricted share units are scheduled to vest immediately prior to the next annual meeting of shareholders, at which point they will be settled in common shares of Bausch + Lomb Corporation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard practice across industries, particularly in the pharmaceutical and medical device sectors, to incentivize long-term commitment and align leadership interests with shareholder value. This practice is consistent with broader corporate governance trends.

Comparison to Industry Standards

• The grant of restricted share units to a non-employee director is a common compensation practice, comparable to similar equity incentive programs at peer companies in the healthcare and pharmaceutical sectors, such as Johnson & Johnson or Medtronic, which frequently use RSUs to compensate their independent directors.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant to a director is intended to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The restricted share units are scheduled to vest immediately prior to the next annual meeting of shareholders.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a non-employee director, which is a standard compensation practice and does not present new information that would significantly alter the investment thesis for Bausch + Lomb. It reinforces alignment but is not a catalyst for a strong buy or sell recommendation.

Keywords

Bausch + Lomb, BLCO, Steven H. Collis, Restricted Share Units, RSU Grant, Director Compensation, Insider Transaction, Form 4, Equity Incentive Plan